Mazdutide vs Tirzepatide
An approved-in-China dual agonist against the most effective FDA-approved weight-management drug available — real efficacy data on both sides, but very different regulatory maturity.
Mazdutide
A GLP-1/glucagon dual agonist approved in China for both obesity and type-2 diabetes, with real Phase 2/3 efficacy data — but still investigational in the US, where no approval application has cleared.
Full Mazdutide evidence reviewTirzepatide
Zepbound / Mounjaro
Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.
Full Tirzepatide evidence reviewSide by side
| Mazdutide | Tirzepatide | |
|---|---|---|
| Marketed for | Weight loss, type-2 diabetes | Weight loss, type-2 diabetes |
| Evidence grade | Clinical data | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | Phase 2 obesity RCT, 2023 | SURMOUNT-1, NEJM 2022 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Tirzepatide is the benchmark: FDA-approved, up to ~21% mean weight loss in SURMOUNT-1, the strongest approved option available today. Mazdutide is a genuine GLP-1/glucagon dual agonist with real Phase 2/3 efficacy data and an actual approval — in China, for both obesity and type-2 diabetes — but it remains fully investigational in the US with no cleared application. They've never been compared head-to-head.
Mazdutide fits if
You're tracking the pipeline of dual-mechanism agonists reaching approval anywhere in the world, not looking for a US prescription.
Tirzepatide fits if
You want the option with FDA approval and the deepest published efficacy record available today.